Agreement covers the establishment of a national programme to enable U.S. healthcare providers the ability to access and order the Renalytix kidneyintelX.dkd test.
Several life sciences companies honored at 2026 Utah Business Innovation Awards.
BXCL501, a novel dexmedetomidine sublingual film, is under FDA review for potential at-home (outpatient) use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Shipments of laboratory equipment and other mosquito abatement materials to overseas USAF base represent first international expansion of Vector Smart product line.
U.S. Representative Celeste Maloy (R-UT) on Aug. 19 toured the Biologic Input Output Systems (BIOS) lab, part of the University of Utah’s Craig H. Neilsen Rehabilitation Hospital, to observe research into prosthetics innovation. Led by University of Utah NeuroRobotics Lab Director and BIOS Chief Scientist Jacob “Jake” George, alongside BIOS Chief Development Officer Tim Miller, […]
Ecopipam (EBS-101) is a first-in-class selective D1 (dopamine) receptor antagonist with Orphan Drug designation
SALT LAKE CITY, Aug. 19, 2026 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced today that Scott Gleason has been appointed Chief Financial Officer (CFO), effective August 31, 2026. Mr. Gleason brings more than 25 […]
Sheri Lewis has agreed to join Merit as Executive VP of Global Operations, effective August 31.
Utah lawmakers on Aug, 19 attended a breakfast meeting of the Utah Life Sciences Innovation Caucus (ULSIC).
Combined operations deliver unified trial delivery, faster recruitment, and expanded evidence-generation capabilities.
The award supports innovative, high-impact research aimed at advancing the prevention, diagnosis, and treatment of breast cancer.
Survival benefit is concentrated in participants with NfL biomarker response.
In-vitro studies confirmed revolutionary therapy successfully disguised liver cancer cells as virally infected cells and activated pre-existing human antiviral Killer T-cells.
Teledyne will acquire all of the outstanding common shares of Varex for $18.90 per share, payable in cash.
BioUtah and BYU’s College of Life Sciences hosted the annual BYU/BioUtah Networking Lunch on August 7 at BYU’s Life Sciences Building in Provo. Nearly 100 people attended out of more than 100 registrants, bringing together life sciences companies from across the state with BYU’s research and tech transfer community. The lunch is one piece of […]
STAT delivers U.S. Government Advocacy for Foreign Investment & Concession Projects
For more than 30 years, AIM has been Europe’s most successful growth market.
Receptor.AI and Sethera partner to create a closed-loop drug discovery workflow.
The Recursion option follows several years of work building what Recursion calls “maps of biology.“
Round brings total capital raised to over $240M.
Funding Brings Total Raised to $47.5M as Demand Grows for Better Infrastructure to Support Biopharma
Submission includes a concurrent CLIA Waiver by Application for use of the test on the Co-Dx PCR Pro® instrument in decentralized point-of-care settings.
A company still awaiting its first FDA clearance just structured a capital raise around the urgency of that wait. On July 30, 2026, Co-Diagnostics, Inc. entered into a warrant inducement agreement with existing warrant holders, convincing them to exercise warrants early in exchange for new warrants at revised terms. The transaction is straightforward on its […]
ARUP Laboratories observed Cyclospora positivity rates increase from very low levels to unprecedented levels within a short period of time.
Investment will support commercialization of GPX and ULTRA Embolic Devices and development of IMPASS neurovascular platform.
Canyon Labs strengthens its commitment to medical device manufacturers with strategic, direct-access leadership investments.
Southern Metrics is led by Chris Lyons, its Chief Executive Officer, an experienced medical technology executive and strategic advisor who has served on the SINTX Board of Directors since April 2025.
Independent industry recognition highlights the Company’s revolutionary immunotherapy platform and growing momentum in precision cancer treatment.
Global medical device quality executive brings more than 30 years of experience building high-performing organizations, advancing quality excellence and supporting scalable growth.
Company also completes proof of concept for the first blood-borne test for Ebola on Co-Dx PCR Pro ® instrument.
ReNU syndrome was discovered in 2024 and there are no medicines approved for the condition.
Company completes design and in-vitro validation of a single Smart mRNA that disguises cancer as multiple viral infections simultaneously to activate pre-existing T-cell immunity.
